UK markets close in 5 hours 4 minutes

Bone Therapeutics SA (0R55.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.2640-0.0105 (-3.83%)
As of 03:20PM BST. Market open.
Full screen
Previous close0.2745
Open0.2895
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.2640 - 0.2895
52-week range0.2640 - 0.2895
Volume219
Avg. volumeN/A
Market cap26,982
Beta (5Y monthly)0.22
PE ratio (TTM)N/A
EPS (TTM)-0.7670
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic

    INSIDE INFORMATION The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company 51% of Medsenic shares (valued at ca EUR 40 million) to be contributed at a subscription price per share of EUR 0.45 Each existing share to be entitled to subscribe to one additional share at EUR 0.45 in case of successful ALLOB interim results Bone Therapeutics to acquire the remaining outstanding capital of Medsenic within 36 months Mon

  • Globe Newswire

    Bone Therapeutics SA: Information on the total number of voting rights and shares

    REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 29 July 2022, 7:30am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs) issued on 9 June 2022. The following information is published in accordance with Article 15 of the Belgi

  • Globe Newswire

    Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

    PRESS RELEASE - INSIDE INFORMATION Recent medical publications provide new insights in timing and dynamics of fracture healing using early radiological assessment With the improved statistical analysis, the number of required patients could be reduced by 20% An interim analysis will be added to the study providing an early assessment of ALLOB’s efficacy based on radiological data of the first 66 evaluable patients and more stringent efficacy end point criteria Mont-Saint-Guibert, Belgium, 15 Jul